Sanofi (SNY) Common Equity (2009 - 2026)
Sanofi (SNY) posted Common Equity of $80.9 billion for Q2 2026, down 3.13% sequentially from $83.5 billion in Q4 2025, and up 1.65% YoY from $79.6 billion in Q2 2025.
Sanofi (SNY) Common Equity (2009 - 2026) Analysis & Trends
Sanofi has reported Common Equity for 18 years, with the latest figure at $80.9 billion in Q2 2026.
- Quarterly Common Equity rose 1.65% year-over-year to $80.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $80.9 billion (up 1.65% YoY) and the FY2025 annual result came in at $83.5 billion, up 0.78% from the prior year.
- Common Equity eased to $80.9 billion in Q2 2026 per SNY's latest filing, from $83.5 billion in the prior quarter.
- Over five years, Common Equity peaked at $83.5 billion in Q4 2025 and troughed at $76.1 billion in Q2 2022.
- A 5-year average of $79.6 billion and a median of $79.6 billion in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity declined 2.89% in 2022, then advanced 4.41% in 2023.
- Over 5 years, Common Equity stood at $76.3 billion in 2022, then rose by 4.41% to $79.7 billion in 2023, then gained by 3.97% to $82.8 billion in 2024, then climbed by 0.78% to $83.5 billion in 2025, then retreated by 3.13% to $80.9 billion in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $80.9 billion, $83.5 billion, and $79.6 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 80.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.86 Bn |
| Dec 31, 2025 | 83.47 Bn |
| Jun 30, 2025 | 79.55 Bn |
| Dec 31, 2024 | 82.82 Bn |
| Jun 30, 2024 | 78.61 Bn |
| Dec 31, 2023 | 79.66 Bn |
| Jun 30, 2023 | 79.43 Bn |
| Dec 31, 2022 | 76.30 Bn |
| Jun 30, 2022 | 76.09 Bn |
| Dec 31, 2021 | 78.57 Bn |
| Jun 30, 2021 | 76.15 Bn |
| Dec 31, 2020 | 75.24 Bn |
| Jun 30, 2020 | 69.93 Bn |
| Dec 31, 2019 | 65.56 Bn |
| Jun 30, 2019 | 63.51 Bn |
| Dec 31, 2018 | 67.38 Bn |
| Mar 31, 2018 | 71.57 Bn |
| Dec 31, 2017 | 68.57 Bn |
| Jun 30, 2017 | 63.55 Bn |
| Dec 31, 2016 | 62.33 Bn |